CPT® Code 81162

BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (ie, detection of large gene rearrangements)

Molecular genetic testing is a critical procedure used to identify mutations in the BRCA1 and BRCA2 genes, which are essential for maintaining genomic stability. The BRCA1 gene is located on chromosome 17, while the BRCA2 gene is found on chromosome 13. Both genes function as tumor suppressors, playing a vital role in preventing uncontrolled cell growth and facilitating the error-free repair of chromosomal damage, particularly in the context of DNA double-strand breaks. When mutations occur in these genes, their ability to repair damaged DNA is compromised, leading to unchecked cellular proliferation. This malfunction is significantly associated with an elevated risk of developing early-onset breast and ovarian cancers in females, as well as certain other cancers in both males and females. The prevalence of mutations in the BRCA1 and BRCA2 genes is notably higher in specific populations, including Norwegian, Dutch, Icelandic, and Ashkenazi Jewish individuals. Genetic testing for these mutations is crucial as it can help identify hereditary cancer syndromes, guide appropriate treatment options, and inform family members about their potential risk of carrying similar mutations. The CPT® Code 81162 encompasses a comprehensive analysis that includes both full sequence analysis and full duplication/deletion analysis, which is essential for detecting large gene rearrangements. The testing typically involves the analysis of whole blood or buccal cells, allowing for a thorough examination of the gene structure, including the identification of point mutations or single nucleotide polymorphisms. This detailed genetic analysis is vital for understanding the implications of BRCA1 and BRCA2 mutations in cancer risk and management.